GLPwatch
SIRT1 as a Therapeutic Target in Diabetic Complications.
Curr Med Chem · 2018
Last updated 2026-05-28Sirtuin1 is an enzyme that helps control how cells respond to energy changes, affecting functions like inflammation and cell aging, which are linked to diabetes complications. Lower levels of Sirtuin1 are tied to problems like blood vessel damage and erectile dysfunction in diabetes. Some natural compounds and diabetes medications, including metformin, exenatide, and liraglutide, may increase Sirtuin1 levels.
AI summary of the abstract below.
| Journal | Curr Med Chem, 2018 |
|---|---|
| Citations | 76 |
| Relative citation ratio | 4.03 |
| NIH percentile | 89 |
| Molecules | — |
| Conditions studied | Type 2 Diabetes, Chronic Kidney Disease |
Abstract
BACKGROUND: Sirtuin1 is an epigenetic enzyme involved in histone and nonhistone protein deacetylation. It acts primarily as a metabolic sensor, which responses to changing energy status by deacetylating crucial transcription factors and cofactors. In this way, Sirtuin1 regulates mitochondrial function and biogenesis, oxidative stress, inflammation, apoptosis and cellular senescence. Disturbance of all of these phenomena promotes the pathogenesis of diabetic complications. These disorders are inseparably connected with chronic hyperglycemia, which possesses a strong epigenetic determinant.
OBJECTIVE: To summarize the contemporary knowledge regarding the role of Sirtuin1 in the development, progression and therapy of diabetic complications.
METHODS: We extensively searched literature describing the importance of Sirtuin1 in pathophysiology and treatment of all kinds of diabetic complications till September 2017. We focused on the examples of synthetic and natural compounds-mediated Sirtuin1 upregulation along with Sirtuin1-associated epigenetics.
RESULTS: Reduction of Sirtuin1 is implicated in endothelial dysfunction and metabolic memory, underlying the development of micro- and macrovascular complications. Declined Sirtuin1 also participates in diabetic testicular and erectile dysfunction. Sirtuin1 is elevated by naturally occurring anti-oxidant and anti-inflammatory compounds such as resveratrol, trans-δ-viniferin, vitamin D and more. Similarly, Sirtuin1 level increases after treatment with standard antihyperglycemic (metformin, exenatide, liraglutide), antihypertensive (sartans), lipid-lowering (fibrates, statins) and anticoagulant (fidarestat) drugs. Regarding epigenetics, a number of miRNAs trigger Sirtuin1 decrease, which further contributes to histone acetylation of Sirtuin1-regulated and relevant for diabetes genes.
CONCLUSION: Evidence strongly suggest that Sirtuin1 upregulation may serve as a potent therapeutic approach against development and progression of diabetic complications.
Verbatim abstract via PubMed 29110598 ↗